Press Release

Medi-Tech Insights

Global Drug Discovery Software Market valued at $2 billion in 2020, is poised to grow at a lucrative CAGR of 14% to reach $3.5 billion by 2025

May 31st, 2022 10:57 AM

The global drug discovery software market (such as ligand-based design, structure-based design, LIMS, ELN) is driven by the increasing R&D spend and pipeline, expanding scope and scale, increasing stringency of testing and regulations, growing number and size of biotechs, need for increasing cost efficiencies and reducing time to market, and move towards web/cloud-based software.

Drug Discovery Software Market – Niche but Fast-Growing Market

The drug discovery software market is niche and growing rapidly, driven by the rising pressure on the pharma and biotech companies to cut costs in the research and preclinical stage of drug development, reduce timelines and improve transparency through deep learning software tools.

Large players present in this segment are trying to consolidate the market by becoming a one stop shop. Moreover, companies are also considering to combine their solutions with bioinformatics and LIMS tools to have a competitive edge.” – Executive, Leading Drug Discovery Software Provider, US

Increasing Focus on Developing AI/ML platforms for Drug Discovery

The life sciences industry is increasingly recognizing the benefits offered by big data and AI/ML in drug discovery. Several AI/ML developments could be seen recently that are expected to disrupt the current drug discovery landscape. For instance, in Mar 2021, insitro, a ML-driven drug discovery and development company raised $400 million. In 2020, Optibrium launched Cerella, an AI software platform for drug discovery.

Increasing Demand for Software Solutions Specifically Designed for Biologics Sector

Biologics are expected to experience strong growth in the drug discovery phase. 50% of drugs currently in the preclinical phase are biologics. To leverage growth opportunities, companies are entering/expanding into biologics software space.

Transition to Web/Cloud-based Software

The drug discovery software market is slowly moving towards cloud-based solutions as it can address most of the issues with on-premise installations and provide quick deployment, minimum upfront costs, high flexibility and scalability making it affordable for even small and medium size pharma/biotechs, academic research/universities and CROs.

Competitive Landscape Analysis: Drug Discovery Software Market

The global drug discovery software market is highly competitive and fragmented. Some of the key players operating in this market are Dassault Systèmes, LabVantage, PerkinElmer, Schrodinger, Abbott, Healx, Optibrium, Instem, Chemical Computing Group, dotmatics, idbs, Titian, Biovia, Celsius, Genome Biologics, Atomwise, Standigm, insitro, and CytoReason.

Get Customized Research Report on Drug Discovery Software Market @

Press Release

  • Recent
  • Popular
  • Comments
  • Turbocharger Market Industry Overview, Driving Factors & Carbon Footprint | Vantage Market Research

    Learn More
  • Global Sound Bar Market Size 2022 Scope, Size and Forecast to 2028 | Vantage Market Research

    Learn More
  • Global Smart Lighting Control Systems Market Size 2022 Global Trend, Segmentation and Opportunities, Forecast 2028 | Vantage Market Research

    Learn More
  • Global Cybersecurity Insurance Market Size 2022 Industry Research, Share, Trend, Price, Future Analysis to 2028 | Vantage Market Research

    Learn More
  • Room Dividers and Partition Panels Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2022 to 2030

    Learn More
  • Double Door Fridge Market End-users, Driver, Segmentation And Key Insights Based on Regional Demand till 2028

    Learn More
  • Microtiter Plates Market: Drivers, Revenue, Application Industry Demand Analysis 2028

    Learn More
  • Travel And Expense Management Software Market May see Big Move and Its Key Players

    Learn More